Phase 2 clinical trial

This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...

This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.

Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.

This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...

The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...

The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...

A new Phase 2 trial is testing MK-8690 as a potential subcutaneous treatment for moderate–severe ulcerative colitis, with clinical remission at 12 weeks as the primary goal. Positive results could point to an additional...

Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...

Patients and families with pediatric UC may be interested because the study tests FMT plus partial enteral nutrition as a potential new treatment approach for children who haven’t responded to standard therapy and as a...

Adding structured partial enteral nutrition to advanced drug therapy could offer a non-pharmacologic way to improve short-term, steroid-free remission rates in active Crohn's disease if the trial shows benefit.

This trial targets fibrotic narrowings (strictures) in Crohn’s disease — a common complication without approved drug treatments — so positive results could change care options and reduce the need for surgery.

Cure8 could only read part of this source from gurufocus.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.

Long-term data help patients and clinicians understand whether a biologic maintains benefit and safety over years. Sustained clinical remission and endoscopic healing are important outcomes linked to better long-term...

GLP-1 drugs are being studied as possible treatments for gut conditions beyond weight loss—researchers are exploring whether they can reduce gut inflammation or improve related liver disease. Patients with IBD, IBS, or...

This article reports an investigational stem cell therapy (StemSmart MSCs) showing safety and clinical responses in a small group of patients with fistulising Crohn’s disease — a serious complication that’s often hard to...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...

A new investigational drug (EOM613) is entering a small Phase II trial for Crohn’s disease, which could become a future treatment option if later studies are positive. Early-stage industry updates can indicate where...

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. Open the original article for the full...

Cure8 found this source from tmcnet.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture. Open the original article for the full details.

Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture. Open the original article for the full details.

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

Cure8 found this source from precisionmedicineonline.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...

This reports a company moving a MAP-targeted antibiotic-like therapy (RHB-204, related to RHB-104) into a Phase 2 trial for Crohn’s disease with mucosal healing and MAP eradication as key endpoints—topics that could...

This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...

This report describes an investigational drug that appears to reach its intestinal target and produced molecular changes in biopsies from people with fibrostenosing Crohn’s — a form that causes scarring and strictures.

Adaptive platform trials could speed testing of multiple Crohn’s treatments and make it easier to compare options, which may shorten the time to find effective therapies. The article outlines design choices and...

The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...

The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.

This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit...

New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...

This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...

A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...

New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...

Early Phase 2 data suggest VTX958 may improve endoscopic healing and lower inflammatory markers in Crohn’s disease, outcomes that matter for long-term disease control. The report also notes the trial missed its primary...

This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...

This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...

A study aiming to identify who is likely to develop Crohn’s disease and to test preventing it could eventually allow truly early treatment before symptoms begin. If successful, validated biomarkers and a risk score could...

This project aims to detect Crohn’s before symptoms appear and test preventive treatment—research that could change diagnosis and care for people with family risk. Successful biomarkers could allow earlier monitoring or...